Rockville, Maryland — October 1, 2026 Demand for blood collection tubes designed for liquid biopsy is accelerating as the market expands from USD 188.4 million in 2026 to USD 1.13 billion by 2036, reflecting a 19.6% CAGR. The market is benefiting from the growing clinical use of liquid biopsy in oncology, increasing availability of cleared molecular assays, and pharmaceutical investment in companion diagnostics and biomarker-driven clinical research. Fact.MR estimates an absolute dollar opportunity of USD 939.6 million between 2026 and 2036, highlighting the expanding procurement opportunity for specialized pre-analytical collection systems.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
Liquid biopsy is increasingly being incorporated into cancer detection, treatment monitoring, and minimal residual disease assessment, creating recurring demand for tubes capable of preserving sample integrity from collection through molecular analysis. The growing number of FDA-cleared and CE-marked liquid biopsy assays is also encouraging laboratories to adopt validated collection formats. Beyond oncology, the increasing use of non-invasive prenatal testing is broadening the addressable application base, while pharmaceutical companies are procuring standardized tubes for companion diagnostic programs and biomarker-focused clinical trials.
Cell-free DNA blood collection tubes hold the leading position within the product type segment, accounting for 44.8% of the market in 2026. Their dominance reflects the central role of cfDNA analysis in liquid biopsy workflows and their integration into validated clinical assay processes. Oncology diagnostics represents 48.6% of application demand, supported by liquid biopsy use across lung, breast, colorectal, and prostate cancer detection and monitoring. Hospitals account for 42.3% of end-use demand as oncology and pathology departments expand their in-house molecular diagnostic capabilities.
China is projected to record the highest country CAGR at 26.5% through 2036, supported by rapid molecular diagnostic laboratory expansion, cancer screening investments, and increasing domestic liquid biopsy assay development. India follows at 24.5%, with diagnostic laboratory infrastructure, rising cancer diagnosis volumes, and expanding molecular testing access supporting specialized tube procurement. Germany is expected to grow at 22.5%, reflecting established reference laboratory networks, clinical adoption of liquid biopsy in oncology, and supportive reimbursement for molecular diagnostics. The United States and the United Kingdom also maintain important roles, with CAGRs of 18.6% and 16.7%, respectively, reflecting mature clinical adoption, assay expansion, and established diagnostic infrastructure.
The competitive landscape includes Streck, Inc., Qiagen N.V., Roche Holding AG, PreAnalytiX GmbH, and Greiner Bio-One International GmbH. Companies are competing through validated collection technologies, assay compatibility, sample stabilization capabilities, distribution networks, and relationships with diagnostic laboratories and pharmaceutical research organizations.
Multi-analyte stabilization tubes represent an important emerging opportunity as liquid biopsy applications move beyond cfDNA-only analysis toward broader multi-omics workflows. These systems can preserve DNA, RNA, proteins, and extracellular vesicles from a single blood draw, creating potential value for pharmaceutical biomarker studies and clinical applications requiring broader molecular characterization. However, high per-tube costs, limited standardization among pre-analytical workflows, and regulatory complexity remain constraints for wider adoption, particularly in price-sensitive and high-volume screening environments.
Shambhu Nath Jha, Principal Consultant at Fact.MR, describes the market as reaching an inflection point as liquid biopsy transitions from research applications toward clinical use. According to the report, establishing collection tubes as validated components within diagnostic assay workflows can create stronger procurement relationships and switching barriers. This trend places greater emphasis on pre-analytical sample quality, assay compatibility, and standardized collection procedures as liquid biopsy adoption expands across oncology diagnostics, companion diagnostics, and multi-cancer early detection programs.
Unlock Actionable Insights from the Complete Report:
For medical device manufacturers, diagnostic laboratories, pharmaceutical companies, procurement teams, and investors, the market presents opportunities across specialized tube formats, molecular diagnostic infrastructure, and emerging multi-omics applications. China and India offer particularly rapid expansion, while Germany provides a strong European market supported by established laboratory networks and clinical adoption. The detailed Fact.MR report evaluates product types, applications, end-use segments, technologies, sample types, distribution channels, regional markets, country-level growth, and competitive developments through 2036.
Explore More Related Studies Published by Fact.MR Research
Tamper-Evident Syringe Caps Market
Wearable Infusion Adhesives Market
Smoke-Evacuating Trocars Market
About Fact.MR
Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes food and beverage, healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, and packaging.
Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.
Media Contact
Fact.MR
Email: sales@factmr.com
Phone: +1 (628) 251-1583
Website: www.factmr.com
